Drug Profile
Mosapride/rebamipide - IlDong Pharmaceutical
Alternative Names: Motireb; Motireb - IlDong pharmaceuticals; Rebamipide/mosaprideLatest Information Update: 19 Feb 2022
Price :
$50
*
At a glance
- Originator Ildong Pharmaceutical
- Class Antiulcers; Gastrokinetics; Morpholines; Small molecules
- Mechanism of Action Mucin stimulants; Oxygen radical formation antagonists; Prostaglandin agonists; Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyspepsia
Most Recent Events
- 19 Feb 2022 No development reported - Phase-III for Dyspepsia in South Korea (PO)
- 07 Sep 2016 Chemical structure information added
- 01 Apr 2016 Phase-III clinical trials in Dyspepsia in South Korea (PO) (NCT02831543)